RosárioPW, Souza CôrtesMC. 2020. Re: “The de novo detection of anti-thyroglobulin antibodies and differentiated thyroid cancer recurrence” by Yin et al. Thyroid, 30:1685–1686.
2.
YinN, ShermanSI, PakY, LitofskyD, GianoukakisA. 2020. The de novo detection of anti-thyroglobulin antibodies and differentiated thyroid cancer recurrence. Thyroid, 30:1490–1495.
3.
CôrtesMCS, RosarioPW, OliveiraLFF, CalsolariMR. 2018. Clinical impact of detectable antithyroglobulin antibodies below the reference limit (borderline) in patients with papillary thyroid carcinoma with undetectable serum thyroglobulin and normal neck ultrasonography after ablation: a prospective study. Thyroid, 28:229–235.
4.
ReverterJL, Rosas-AllendeI, Puig-JoveC, ZafonC, MegiaA, CastellsI, PizarroE, Puig-DomingoM, GranadaML. 2020. Prognostic significance of thyroglobulin antibodies in differentiated thyroid cancer. J Thyroid Res 8312628.
5.
FatemiS, LoPrestiJ, DlottR, PetrovicI, SpencerCA. 2019. High DTC recurrence and mortality for patients with de novo appearance or re appearance of thyroglobulin autoantibodies (TgAb) during long term follow-up. Thyroid, 29 (Suppl 1):A87.
